News summary

Nference and Novo partner to advance understanding of cardiometabolic disease and healthy ageing

Source: PR Newswire • Published: 18 Nov 2026, 10:30

Summarized by Masters of Longevity from PR Newswire.

They will combine trial and real-world data with AI analytics.

Nference and Novo partner to advance understanding of cardiometabolic disease and healthy ageing
Key Takeaways
  • The partnership is combining Novo trial data with nference AI.
  • Research is studying treatment effectiveness, safety, and progression.
  • A venture framework was created to support AI-native cardiometabolic firms.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.